Targeting GSK-3 family members in the heart: A very sharp double-edged sword

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 607-613

  Cheng, Hui ^a   Woodgett, James ^b   Maamari, Mia ^a   Force, Thomas ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cardiac hypertrophy; Glycogen synthase kinase 3; Metabolism; Therapeutic potential

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; BIO; CHIR 98014; CHIR 99021; CT 118637; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; L 803 MTS; LITHIUM; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; BIPOLAR DISORDER; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG INDUSTRY; DRUG TARGETING; GENE DELETION; GLYCOGEN SYNTHESIS; HEART INJURY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATORY DISEASE; ISCHEMIC PRECONDITIONING; NEOPLASM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SPINOCEREBELLAR DEGENERATION;

ANIMALS; CARDIOMEGALY; CELL DIFFERENTIATION; CELL PROLIFERATION; DIABETES MELLITUS; EMBRYONIC STEM CELLS; GENE DELETION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN RESISTANCE; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN KINASE INHIBITORS; TRANSLATIONAL MEDICAL RESEARCH; VENTRICULAR REMODELING;

MUS;

EID: 80052816865     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.11.020     Document Type: Review

References (65)

1. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990, 9:2431-2438.
2. Woodgett J.R., Cohen P. Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta 1984, 788:339-347.
3. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186.
4. Sugden P.H., Fuller S.J., Weiss S.C., Clerk A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol Mar 2008, 153(Suppl 1):S137-S153.
5. Bikkavilli R.K., Feigin M.E., Malbon C.C. p38 mitogen-activated protein kinase regulates canonical Wnt-beta-catenin signaling by inactivation of GSK3beta. J Cell Sci Nov 1 2008, 121(Pt 21):3598-3607.
6. Thornton T.M., Pedraza-Alva G., Deng B., Wood C.D., Aronshtam A., Clements J.L., et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science May 2 2008, 320(5876):667-670.
7. Haq S., Choukroun G., Kang Z.B., Lee K.-H., Ranu H., Matsui T., et al. Glycogen synthase kinase-3ß is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000, 151:117-129.
8. Morisco C., Zebrowski D., Condorelli G., Tsichlis P., Vatner S.F., Sadoshima J. The Akt-glycogen synthase kinase 3ß pathway regulates transcription of atrial natriuretic factor induced by ß-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem 2000, 275:14466-14475.
9. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., Sadoshima J. Glycogen synthase kinase 3ß regulates GATA4 in cardiac myocytes. J Biol Chem 2001, 276:28586-28597.
10. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., et al. Activated glycogen synthase kinase-3ß suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci 2002, 99:907-912.
11. Haq S., Michael A., Andreucci M., Bhattacharya K., Dotto P., Walters B., et al. Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci USA Apr 15 2003, 100(8):4610-4615.
12. Hirotani S., Zhai P., Tomita H., Galeotti J., Marquez J.P., Gao S., et al. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res Nov 26 2007, 101(11):1164-1174.
13. Matsuda T., Zhai P., Maejima Y., Hong C., Gao S., Tian B., et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci USA Dec 30 2008, 105(52):20900-20905.
14. Michael A., Haq S., Chen X., Hsich E., Cui L., Walters B., et al. Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem May 14 2004, 279(20):21383-21393.
15. Sanbe A., Gulick J., Hanks M.C., Liang Q., Osinska H., Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003, 92:609-616.
16. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3beta activity. Nat Med 2007, 13:324-331.
17. Zhai P., Gao S., Holle E., Yu X., Yatani A., Wagner T., et al. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem Nov 9 2007, 282(45):33181-33191.
18. Murphy E., Steenbergen C. Does inhibition of glycogen synthase kinase protect in mice?. Circ Res Aug 1 2008, 103(3):226-228.
19. Murphy E., Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev Apr 2008, 88(2):581-609.
20. Juhaszova M., Zorov D.B., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res Jun 5 2009, 104(11):1240-1252.
21. Kerkela R., Kockeritz L., Macaulay K., Zhou J., Doble B.W., Beahm C., et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest Nov 2008, 118(11):3609-3618.
22. Woulfe K.C., Gao E., Lal H., Harris D., Fan Q., Vagnozzi R., et al. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res May 28 2010, 106(10):1635-1645.
23. Zhou J., Lal H., Chen X., Shang X., Song J., Li Y., et al. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest Jul 1 2010, 120(7):2280-2291.
24. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature Jul 6 2000, 406(6791):86-90.
25. Force T., Woodgett J.R. Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem Apr 10 2009, 284(15):9643-9647.
26. Webb I.G., Sicard P., Clark J.E., Redwood S., Marber M.S. Myocardial stress remodelling after regional infarction is independent of glycogen synthase kinase-3 inactivation. J Mol Cell Cardiol Nov 2010, 49(5):897-900.
27. Webb I.G., Nishino Y., Clark J.E., Murdoch C., Walker S.J., Makowski M.R., et al. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart. Cardiovasc Res Aug 1 2010, 87(3):494-503.
28. Chen X., Shevtsov S., Hsich E., Cui L., Haq S., Aronovitz M.J., et al. The β-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol 2006, 26:4462-4473.
29. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med Jan 2004, 10(1):55-63.
30. Ying Q.L., Wray J., Nichols J., Batlle-Morera L., Doble B., Woodgett J., et al. The ground state of embryonic stem cell self-renewal. Nature May 22 2008, 453(7194):519-523.
31. Doble B.W., Patel S., Wood G.A., Kockeritz L.K., Woodgett J.R. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell Jun 2007, 12(6):957-971.
32. Ahuja P., Zhao P., Angelis E., Ruan H., Korge P., Olson A., et al. Myc controls transcriptional regulation of cardiac metabolism and mitochondrial biogenesis in response to pathological stress in mice. J Clin Invest May 3 2010, 120(5):1494-1505.
33. Ruel L., Bourouis M., Heitzler P., Pantesco V., Simpson P. Drosophila shaggy kinase and rat glycogen synthase kinase-3 have conserved activities and act downstream of Notch. Nature Apr 8 1993, 362(6420):557-560.
34. Siegfried E., Chou T.B., Perrimon N. wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate. Cell Dec 24 1992, 71(7):1167-1179.
35. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc Aug 2009, 84(8):718-729.
36. Tseng A.S., Engel F.B., Keating M.T. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol 2006, 13:957-963.
37. Eldar-Finkelman H., Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci 1997, 94:9660-9664.
38. Liberman Z., Eldar-Finkelman H. Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J Biol Chem Feb 11 2005, 280(6):4422-4428.
39. Dokken B.B., Sloniger J.A., Henriksen E.J. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab Jun 2005, 288(6):E1188-E1194.
40. Henriksen E.J., Kinnick T.R., Teachey M.K., O'Keefe M.P., Ring D., Johnson K.W., et al. Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab May 2003, 284(5):E892-E900.
41. Leng S., Zhang W., Zheng Y., Liberman Z., Rhodes C.J., Eldar-Finkelman H., et al. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. J Endocrinol Aug 2010, 206(2):171-181.
42. Liu Y., Tanabe K., Baronnier D., Patel S., Woodgett J., Cras-Meneur C., et al. Conditional ablation of Gsk-3beta in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice. Diabetologia Dec 2010, 53(12):2600-2610.
43. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol Mar 2009, 156(6):885-898.
44. Dokken B.B., Henriksen E.J. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats. Am J Physiol Endocrinol Metab Aug 2006, 291(2):E207-E213.
45. Ring D.B., Johnson K.W., Henriksen E.J., Nuss J.M., Goff D., Kinnick T.R., et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes Mar 2003, 52(3):588-595.
46. Kaidanovich-Beilin O., Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther Jan 2006, 316(1):17-24.
47. Rao R., Hao C.M., Redha R., Wasserman D.H., McGuinness O.P., Breyer M.D. Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia Feb 2007, 50(2):452-460.
48. Pearce N.J., Arch J.R., Clapham J.C., Coghlan M.P., Corcoran S.L., Lister C.A., et al. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism Oct 2004, 53(10):1322-1330.
49. MacAulay K., Doble B.W., Patel S., Hansotia T., Sinclair E.M., Drucker D.J., et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab Oct 2007, 6(4):329-337.
50. Patel S., Doble B.W., MacAulay K., Sinclair E.M., Drucker D.J., Woodgett J.R. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol Oct 2008, 28(20):6314-6328.
51. Mussmann R., Geese M., Harder F., Kegel S., Andag U., Lomow A., et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem Apr 20 2007, 282(16):12030-12037.
52. Stukenbrock H., Mussmann R., Geese M., Ferandin Y., Lozach O., Lemcke T., et al. 9-cyano-1-azapaullone (cazpaullone), a glycogen synthase kinase-3 (GSK-3) inhibitor activating pancreatic beta cell protection and replication. J Med Chem Apr 10 2008, 51(7):2196-2207.
53. Liu Z., Tanabe K., Bernal-Mizrachi E., Permutt M.A. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. Diabetologia Apr 2008, 51(4):623-631.
54. Han S.I., Aramata S., Yasuda K., Kataoka K. MafA stability in pancreatic beta cells is regulated by glucose and is dependent on its constitutive phosphorylation at multiple sites by glycogen synthase kinase 3. Mol Cell Biol Oct 2007, 27(19):6593-6605.
55. Tanabe K., Liu Z., Patel S., Doble B.W., Li L., Cras-Meneur C., et al. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol Feb 2008, 6(2):e37.
56. Mora A., Sakamoto K., McManus E.J., Alessi D.R. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett Jul 4 2005, 579(17):3632-3638.
57. Wang Y., Feng W., Xue W., Tan Y., Hein D.W., Li X.K., et al. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes Jun 2009, 58(6):1391-1402.
58. Omar M.A., Wang L., Clanachan A.S. Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload. Cardiovasc Res Jun 1 2010, 86(3):478-486.
59. Haq S., Choukroun G., Lim H.W., Tymitz K.M., del Monte F., Gwathmey J., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001, 103:670-677.
60. Baba H.A., Stypmann J., Grabellus F., Kirchhof P., Sokoll A., Schafers M., et al. Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human endstage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 2003, 59:390-399.
61. Razeghi P., Bruckner B.A., Sharma S., Youker K.A., Frazier O.H., Taegtmeyer H. Mechanical unloading of the failing human heart fails to activate the protein kinase B/Akt/glycogen synthase kinase-3beta survival pathway. Cardiology 2003, 100:17-22.
62. Razeghi P., Taegtmeyer H. Activity of the Akt/GSK-3beta pathway in the failing human heart before and after left ventricular assist device support. Cardiovasc Res 2004, 61:196-197.
63. Chen Y., Park S., Li Y., Missov E., Hou M., Han X., et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics Aug 15 2003, 14(3):251-260.
64. Tateishi K., Ashihara E., Honsho S., Takehara N., Nomura T., Takahashi T., et al. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun Jan 19 2007, 352(3):635-641.
65. Buescher J.L., Phiel C.J. A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem Mar 12 2010, 285(11):7957-7963.